Moderna Q3 2026 earnings

MRNA · 2026-11-06 06:47 BMO ET · 8-K on SEC

Revenue growth accelerated to 29% in Q3, and the company achieved GAAP profitability, while guidance was raised to 15%-25% growth and cash balance was significantly improved.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$1.3B+29%+795.7%Ex. 99.1, income statement
EPS (GAAP)$0.38vs $(0.51) lossN/AEx. 99.1, income statement
Net income$0.2B$362M improvementN/AEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
U.S.$780M+80.1%59.4%—
International$533M+46.9%40.6%—

Margins and costs

  • Gross margin N/A
  • Operating expenses $1.2B (+7.4% YoY)
  • One-offs in the quarter Litigation settlement charge of $0.9B included in 2026 cost of sales guidance; Convertible notes offering proceeds of $2.6B net
  • Effective tax rate N/A
  • Non-GAAP bridge N/A

KPIs

MetricActualPrior quarterPrior yearChange
Cash, cash equivalents and investments$8.0B$6.9BN/A+$1.1B
Weighted average common shares (diluted)430M398M390M+10.1%

Guidance

MetricGuidePrior guideChange
Revenue growth15%–25%Up to 10%Increased
Cost of sales (full year)Approximately $1.7BApproximately $1.7BUnchanged
R&D expenses (full year)Approximately $2.7BApproximately $2.9BReduced
SG&A expenses (full year)Approximately $1.0BApproximately $1.0BUnchanged
Capital expenditures (full year)Approximately $0.2B to $0.3BApproximately $0.2B to $0.3BUnchanged
Year-end cash and investments$8.1B to $8.3B$4.7B to $5.2BIncreased

What drove it

  • Revenue story Revenue increased 29% YoY to $1.3B, driven by higher COVID vaccine sales in international markets and deliveries under long-term strategic government partnerships.
  • EPS story EPS improved from a loss of $(0.51) to a profit of $0.38, driven by higher revenue and improved operating income.
  • One-off check Litigation settlement charge of $0.9B included in 2026 cost of sales guidance.

The good

  • Revenue growth accelerated to 29% in Q3
  • Achieved GAAP net income of $162M and EPS of $0.38
  • Raised full-year revenue growth guidance to 15%-25%
  • Increased year-end cash balance guidance to $8.1–$8.3B
  • Received U.S. FDA approval for mFLUSIVA, the fifth approved product

The bad

  • Cost of sales increased 54% YoY due to higher product volume and manufacturing costs
  • SG&A expenses increased 5% YoY

The ugly

  • none

Open questions

  • The filing does not disclose the specific revenue mix between COVID and seasonal flu vaccines in Q3.
  • The filing does not disclose the specific revenue mix between COVID and seasonal flu vaccines in Q3.
Full release

Moderna (MRNA) earnings release, November 6, 2026

Moderna, Inc. (MRNA) · Form 8-K, Item 2.02 · Filed · SEC filing

Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates

Reports third quarter revenue of $1.3 billion, GAAP net income of $0.2 billion and GAAP diluted EPS of $0.38

Increases 2026 expected revenue growth to 15%–25%, exceeding the previous expectation of up to 10% growth

Improves 2026 GAAP operating expense outlook by approximately $0.2 billion from previous estimate

Increases 2026 expected ending cash balance to $8.1–$8.3 billion

Highlights positive Phase 3 data for intismeran and U.S. FDA approval of mFLUSIVA, the Company's fifth approved product globally

CAMBRIDGE, MA / ACCESSWIRE / November 6, 2026 /

Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2026.

“We delivered 29% revenue growth in the third quarter, alongside the U.S. approval of mFLUSIVA, our fifth approved product globally, and positive Phase 3 results for intismeran in melanoma,” said Stéphane Bancel, Chief Executive Officer of Moderna. “Building on this momentum, we increased our full-year revenue growth outlook to 15%-25%, while continuing to reduce costs and strengthen our balance sheet. Looking ahead, we anticipate additional intismeran readouts, pivotal data in propionic acidemia and further regulatory approvals as we advance our pipeline and build a more diversified company.”

Commercial Strategy

Moderna continued to execute its multi-year revenue growth strategy during the third quarter, supported by the launch of updated COVID vaccines, expansion of its approved respiratory vaccine portfolio and execution of international strategic partnerships with the United Kingdom, Canada and Australia. In September, the Company signed a five-year agreement with a local manufacturer in Mexico for COVID-19 vaccines, supporting recurring revenue and international market expansion.

Third Quarter 2026 Financial Results

Revenue

: Total revenue for the third quarter of 2026 increased 29% to $1.3 billion, compared to $1.0 billion in the same period in 2025, primarily driven by higher COVID vaccine sales in international markets, supported by deliveries under long-term strategic government partnerships. Revenue was $780 million in the U.S. and $533 million in international markets.

Cost of Sales:

Cost of sales for the third quarter of 2026 was $318 million, including $65 million of third-party royalties. Cost of sales increased by 54% compared to the same period in 2025, primarily driven by higher product sales volume and other manufacturing-related costs.¹

Research and Development Expenses:

Research and development expenses for the third quarter of 2026 were $583 million, a 27% decrease compared to the same period in 2025, primarily driven by lower clinical development costs following the completion and wind-down of certain late-stage studies in the Company's infectious disease portfolio, as well as continued cost efficiencies across the organization.

Selling, General and Administrative Expenses:

Selling, general and administrative expenses for the third quarter of 2026 were $282 million, a 5% increase year-over-year. We continue to maintain cost discipline across the organization.

Income Taxes:

Income tax provisions for both periods were not material, as the Company continues to maintain a global valuation allowance against most of its deferred tax assets.

Net Income:

Net income was $162 million for the third quarter of 2026, compared to a net loss of $(200) million in the third quarter of 2025, representing a $362 million improvement year-over-year.

Earnings Per Share:

Diluted earnings per share were $0.38 for the third quarter of 2026, compared to a loss per share of $(0.51) for the third quarter of 2025.

Cash Position:

Cash, cash equivalents and investments as of September 30, 2026, were $8.0 billion, compared to $6.9 billion as of June 30, 2026. The increase primarily reflected $2.6 billion in net proceeds from the issuance of convertible notes and related capped call transactions, partially offset by the $950 million payment related to the litigation settlement announced in the first quarter of 2026, and cash used in operations, including the seasonal working capital impact from third-quarter product sales, the majority of which remained uncollected at quarter-end.

2026 Financial Framework

Revenue:

The Company now expects total revenue growth of 15% to 25% in 2026, exceeding its previous outlook of up to 10% growth. Moderna continues to expect approximately half of its 2026 revenue to come from the United States and half from international markets.

Cost of Sales:

Cost of sales for 2026 is expected to be approximately $1.7 billion, including the previously announced $0.9 billion non-recurring litigation settlement charge.

Research and Development Expenses:

Research and development expenses for 2026 are expected to be approximately $2.7 billion, reduced from the Company's previous expectation of approximately $2.9 billion.

Selling, General and Administrative Expenses:

Selling, general and administrative expenses for 2026 are expected to be approximately $1.0 billion, unchanged from previous forecast.

Income Taxes:

The Company continues to expect negligible income tax expense for 2026.

Capital Expenditures:

Capital expenditures for 2026 are expected to be approximately $0.2 billion, improved from the previous expectation of $0.2 billion to $0.3 billion.²

Cash and Investments:

The Company now expects year-end 2026 cash and investments of approximately $8.1 billion to $8.3 billion, increased from its previous outlook of $4.7 billion to $5.2 billion. The increase reflects improved operational execution and proceeds from the Company’s convertible notes financing. This outlook excludes additional drawdowns from the approximately $0.9 billion remaining available under the Company's credit facility.

Recent Progress and Upcoming Late-Stage Pipeline Milestones

Infectious Disease Vaccines... (truncated)e (mRNA-1010):

In August, Moderna received U.S. Food and Drug Administration (FDA) approval for mFLUSIVA®, its seasonal influenza vaccine, for adults aged 50–64 years and accelerated approval for adults aged 65 years and older, marking the Company's fifth approved product globally. Moderna is conducting a limited U.S. launch for the 2026–2027 influenza season, with approval occurring after the annual contracting cycle. The Company also received approval for mFLUSIVA in Canada.

Flu/COVID Combination Vaccine (mRNA-1083):

Moderna received regulatory approval in Canada for mCOFLU®, the Company's flu/COVID combination vaccine, following approval of the vaccine under the brand name mCOMBRIAX® in the European Union. The vaccine remains under regulatory review in additional markets, including Japan, the United Kingdom and Australia. Moderna continues to await further guidance from the FDA regarding refiling in the United States.

Norovirus Vaccine (mRNA-1403):

Following the Phase 3 interim analysis, which did not meet the statistical criteria for early success, Moderna does not plan to initiate an additional cohort this season. The Company intends to engage with health authorities to determine the program's path forward.

Oncology Therapeutics

Intismeran autogene (mRNA-4157):

In October, Moderna and Merck presented positive Phase 3 results from the INTerpath-001 study in resected high-risk melanoma at the European Society for Medical Oncology (ESMO) Congress 2026. Intismeran autogene in combination with KEYTRUDA® (pembrolizumab) reduced the risk of recurrence or death by 42% (HR=0.58) and the risk of distant metastasis or death by 38% (HR=0.62), compared with KEYTRUDA alone, in the intention-to-treat population. The benefit was greater after six months, following the intismeran immunization regimen, as intismeran plus KEYTRUDA reduced the risk of recurrence or death by 58% (piecewise HR=0.42 [95% CI, 0.30–0.58]) compared to KEYTRUDA alone in a pre-specified sensitivity analysis. Moderna and Merck are working toward regulatory submissions and preparing for a potential commercial launch, subject to regulatory approval. mRNA-4359:

Moderna continues Phase 2 clinical trial of its investigational cancer antigen therapy in first-line metastatic melanoma, previously treated metastatic melanoma and first-line non-small cell lung cancer. mRNA-2808:

Abstract accepted for oral presentation at American Society of Hematology meeting on December 12th in New Orleans.³ mRNA-4203:

Moderna and Immatics continue dosing in a Phase 1 study evaluating mRNA-4203 in combination with anzu-cel (anzutresgene autoleucel, IMA203).

Rare Disease Therapeutics

Propionic Acidemia (mRNA-3927):

The registrational study has reached its target enrollment, with pivotal data expected in 2026.

Methylmalonic Acidemia (mRNA-3705):

Moderna has deferred a decision on initiating a pivotal study until the propionic acidemia registrational study readout.

Moderna Corporate Updates

• Leadership Appointment:

In September, Moderna announced the appointment of Juan Andres as Chief Operating Officer, effective October 5, 2026. Mr. Andres previously served in senior leadership positions at Moderna and will oversee the Company's operational strategy and execution, including its global manufacturing organization.

• Leadership Retirement:

In September, Moderna announced that Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer, retired following four years with the Company.

• Financing:

In September, Moderna completed a convertible senior notes offering totaling approximately $3.0 billion in principal amount. After accounting for the purchase of capped calls designed to mitigate potential future dilution and associated fees, we raised approximately $2.6 billion in net proceeds. The financing provides additional financial flexibility to support continued investment in oncology and address future debt obligations.

• Litigation Settlement:

Moderna and GSK entered into an agreement on October 28, 2026, to settle all disputes between the parties which were pending in the U.S. and Europe. Pursuant to the agreement, the parties granted patent cross-licenses in the field of infectious disease and are not obligated to make payments of any kind in connection with such licenses.

Company Accolades

• Fortune Change the World:

Moderna was named to Fortune's 2026 Change the World list, recognizing the Company's impact through mRNA medicines.

• Science Top Employers:

Moderna was named a top employer in

Science and

Science Careers'

2026 Top Employers Survey for the twelfth consecutive year.

Key 2026 Investor and Analyst Event Dates

• Moderna Analyst Day:

November 12, 2026

Investor Call and Webcast Information

Moderna will host a live conference call and webcast at 8:00 a.m. ET on November 6, 2026. To access the live conference call via telephone, please register at the link below. Once registered, dial-in⁴ numbers and a unique pin number will be provided. A live webcast of the call will also be available under "Events and Presentations" in the Investors section of the Moderna website.

• Telephone

: https://register-conf.media-server.com/register/BI3b0723c2720c4799a951732b6daedea8

• Webcast

: https://investors.modernatx.com

The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.

About Moderna

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.... (truncated)edicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.⁵

Financial statements

Income Statement

Three Months Ended September 30, — (Unaudited, in millions, except per share data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenue:
Net product sales1,2739731,7191,172
Other revenue1404312894
Total revenue1,3131,0161,8471,266
Operating expenses:
Cost of sales3182071,366416
Research and development5838011,8832,357
Selling, general and administrative282268671710
Total operating expenses1,1831,2763,9203,483
Income (loss) from operations130-260-2,073-2,217
Interest income6273201244
Other (expense) income, net-21-584
Income (loss) before taxes171-187-1,930-1,969
Provision for income taxes9133327
Net income (loss)162-200-1,963-1,996
Earnings (loss) per share
Basic0.4-0.51-4.93-5.15
Diluted0.38-0.51-4.93-5.15
Weighted average common shares used in calculation of earnings (loss) per share
Basic401390398388
Diluted430390398388

Balance Sheet

September 30, — (Unaudited, in millions)

September 30, – 2026December 31, – 2025
Current assets:
Cash and cash equivalents1,1952,595
Investments3,9763,204
Accounts receivable, net1,367184
Inventory313153
Prepaid expenses and other current assets493408
Total current assets7,3446,544
Investments, non-current2,8052,336
Property, plant and equipment, net2,0362,134
Right-of-use assets, operating leases687719
Other non-current assets596605
Total assets13,46812,338
Current liabilities:
Accounts payable259317
Accrued liabilities1,3951,386
Deferred revenue26899
Other current liabilities106185
Total current liabilities2,0281,987
Deferred revenue, non-current139153
Operating lease liabilities, non-current630653
Financing lease liabilities, non-current20
Long-term debt591590
Convertible notes2,958
Other non-current liabilities285285
Total liabilities6,6313,688
Stockholders’ equity:
Additional paid-in capital1,5691,382
Accumulated other comprehensive income845
Retained earnings5,2607,223
Total stockholders’ equity6,8378,650
Total liabilities and stockholders’ equity13,46812,338

Cash Flow

Nine Months Ended September 30, — (Unaudited, in millions)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Operating activities
Net loss-1,963-1,996
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation351370
Depreciation and amortization190148
Amortization/accretion of investments-33-54
Loss on equity investments, net25
Other non-cash items1750
Changes in assets and liabilities:
Accounts receivable, net-1,184-703
Prepaid expenses and other assets-28-84
Inventory-159-213
Right-of-use assets, operating leases3128
Accounts payable-32-114
Accrued liabilities35-196
Deferred revenue160108
Operating lease liabilities-23-15
Other liabilities-79-137
Net cash used in operating activities-2,715-2,803
Investing activities
Purchases of marketable securities-5,149-4,221
Proceeds from maturities of marketable securities2,3884,634
Proceeds from sales of marketable securities1,5191,744
Purchases of property, plant and equipment-146-153
Purchase of intangible asset-74-10
Net cash (used in) provided by investing activities-1,4621,994
Financing activities
Proceeds from issuance of convertible notes3,000
Payments for issuance costs related to convertible notes-43
Purchase of capped calls related to convertible notes-329
Proceeds from issuance of common stock through equity plans17219
Tax payments related to net share settlements on equity awards-7-1
Changes in financing lease liabilities-17-6
Net cash provided by financing activities2,77612

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.